Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Alexander Deiters · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2023 · $356,542 — PROJECT SUMMARY The overall goal of this proposal is to develop a fundamentally new class of oligonucleotide agents – covalent aptamers – that will have a major impact on nucleic acid-based reagents and therapeutics. Covalent aptamers will be an enabling methodology behind new aptamer applications a…
VAHRAM HAROUTUNIAN · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2023 · $1,267,500 — PROJECT SUMMARY Alzheimer’s disease (AD) stands out as notable in two respects––in not having a cure and in affecting women more than men. While declining estrogen has been thought to underpin post–menopausal AD, there is a clear clinical correlation of AD with rising levels of follicle–stimulating…
Zachary A Bornholdt · EITR BIOLOGICS, INC. · 2023 · $283,552 — The magnitude and duration of the ongoing COVID-19 pandemic have underscored the need to have a well-equipped—and ideally prepositioned—arsenal of antiviral weapons to mount an adequate public health response. A key lesson is that multiple medical countermeasures (MCMs) are needed to maintain potenc…
NORMAN R HARRIS · LOUISIANA STATE UNIV HSC SHREVEPORT · 2023 · $365,000 — Approximately 32-44% of the adult US population has hypertension, with one of the many complications being hypertensive retinopathy. In one study, the prevalence of retinopathy was found to be 85% amongst those with severe hypertension, and 25% for those with mild hypertension. Retinal consequences …
Arvind Murugan · UNIVERSITY OF CHICAGO · 2023 · $385,136 — Project summary/abstract The success of life on earth derives from its use of molecules to carry information and implement algorithms that control chemistry, allowing organisms to respond adaptively to their environment. The ability to transduce information and respond adaptively ultimately relies o…
Thomas Miller Gallagher · LOYOLA UNIVERSITY CHICAGO · 2023 · $244,800 — PROJECT SUMMARY The continuous adaptation of SARS-CoV-2 generates variants of concern (VOC). New VOCs arise independently and outcompete previous ones, consistent with ever increasing viral fitness. Most VOC adaptations reside in the spikes (S), the complex multidomain glycoprotein trimers that bind…
Jeffery Micheal Tharp · INDIANA UNIVERSITY INDIANAPOLIS · 2023 · $249,000 — PROJECT SUMMARY Bicyclic peptides are conformationally constrained peptides comprised of two macrocyclic rings. Owing to their increased rigidity, bicyclic peptides can bind to protein targets with greater affinity and selectivity than their linear and monocyclic counterparts. As a result, these mol…
Dan H. Barouch · FRED HUTCHINSON CANCER CENTER · 2023 · $2,683,830 — FOA: PA-20-272: Administrative Supplements to Existing NIH Grants and Cooperative Agreements Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the …
SAMUEL JEREMY PLEASURE · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2023 · $629,459 — PROJECT SUMMARY COVID-19 is associated with a growing number of peripheral and central nervous system complications. It has become clear that a subset of these syndromes, including acute necrotizing encephalopathy, steroid- responsive encephalitis and Guillain-Barré syndrome, are likely due to dire…
MARCUS AARON HORWITZ · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2023 · $549,664 — Project Summary/Abstract Francisella tularensis is a bacterium that causes tularemia, a disease which, when in its pneumonic form, can be fatal even with appropriate treatment. Due to its low infectious dose, ease of spread by aerosol, and high virulence, F. tularensis is classified as a Tier 1 Sele…
L Lee HAMM · TULANE UNIVERSITY OF LOUISIANA · 2023 · $311,220 — PROJECT SUMMARY This application is a supplement request to our P51 base grant to Tulane National Primate Research Center (TNPRC) to further the investigation of the Post-Acute Sequelae of SARS-CoV-2 infection (PASC). This application investigates the overarching hypothesis that SARS-CoV-2-induced d…
BARSANJIT MAZUMDER · CLEVELAND STATE UNIVERSITY · 2023 · $222,750 — Adopted folding of the RNA elements within the genomes of RNA viruses allows binding of host and viral proteins and plays an essential role in host-virus interactions. However, the mechanistic insights on how these RNA elements could sense the transduced signals from host cells are lacking for SARS-…
Alvin Yu · UNIVERSITY OF CALIFORNIA-IRVINE · 2023 · $249,000 — PROJECT SUMMARY Viruses are infectious agents that replicate inside the living cells of an organism, and it remains critical to understand the basic molecular mechanisms that govern viral replication, as they perform numerous complex physical and chemical processes ranging from atomic-scale phenomen…
YOSHIHIRO KAWAOKA · UNIVERSITY OF WISCONSIN-MADISON · 2023 · $4,618,169 — SUMMARY Most of the vaccines currently approved or in development against the pandemic SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) virus target immunodominant, strain-specific epitopes in the SARS-CoV-2 spike (S) protein and are therefore not expected to confer protection against o…
JUAN M SAAVEDRA · GEORGETOWN UNIVERSITY · 2023 · $623,584 — SARS-CoV-2, the virus underlying the current COVID-19 pandemic, not only affects peripheral tissues, it also targets the brain causing microvascular lesions, microhemorrhages and neurological manifestations. The internalization of SARS-CoV-2 is initiated by the binding of the virus spike protein to …
Gabriela Cristina Brailoiu · TEMPLE UNIV OF THE COMMONWEALTH · 2023 · $476,255 — SARS-CoV-2, the virus that causes COVID-10, impacts multiple organ systems including the central nervous system. Neurological symptoms are seen in about one third of COVID-19 patients and the virus has been found in brain tissue. SARS-CoV-2 uses angiotensin converting enzyme 2 (ACE2) located on cell…
Paul D. Bieniasz · ROCKEFELLER UNIVERSITY · 2023 · $4,259,011 — ABSTRACT-OVERALL The recurrent emergence of coronaviruses from animal reservoirs, and the resulting COVID19 pandemic, necessitates the development of interventions that can target diverse pandemic-threat coronaviruses. Vaccines are among the most powerful means for mitigating viral epidemics but re…
Nitesh K Kunda · ST. JOHN'S UNIVERSITY · 2023 · $164,000 — Summary Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) is a highly infectious virus known to cause the 2019 coronavirus disease (COVID-19). The disease has been declared as a global pandemic by the World Health Organization. In the United States, as of January 20, 2021, we have more th…
Yingjie Chen · PURDUE UNIVERSITY · 2023 · $122,453 — Project Summary Cryo-electron microscopy (cryoEM) revolutionized structural biology, providing a powerful method to study biological specimens in their native environment. However, a major bottleneck hindering the wider use of cryoEM is the lack of trained professionals capable of proficiently opera…
Lisa A Cavacini · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2023 · $694,551 — Project Summary The coronavirus disease 2019 (COVID-19) rapidly disseminated through the human population and became a global pandemic. Significant efforts have been put into developing vaccines or antibody therapies based on the spike glycoprotein of SARS-CoV-2. One challenge of such strategies is …